Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
|Articles|June 12, 2014
EMA to Review Safety of Ibuprofen Medicines
Author(s)The Pharm Exec staff
The European Medicine Agency’s Pharmacovigilance and Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks with systemic ibuprofen medicines.
Advertisement
The European Medicine Agency’s Pharmacovigilance and Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks with systemic ibuprofen medicines.
The cardiovascular risks being evaluated concern high-dose ibuprofen (2,400 mg per day) taken regularly for long periods. There is no suggestion of similar cardiovascular risk in lower doses taken for short periods of time. Long available as an over-the-counter medicine in Europe, ibuprofen has a well-known safety profile.
However, safety of non-steroidal anti-inflammatory drugs (NSAIDs) has been under close EMA review for many years. Data have suggested that the cardiovascular risk with diclofenac and high-dose ibuprofen (2,400 mg) may be similar to the known risk with COX-2 inhibitors (also of the NSAID class).
The PRAC will also evaluate evidence on the interaction of ibuprofen with low-dose aspirin (taken to reduce the risk of heart attacks and strokes) to decide whether current advice to healthcare professionals is sufficient.
Advertisement
Related to this article
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
When Experience, Evidence, and AI Disagree in Pharma, What Should Leaders Do?
4
FDA Launches Rare Disease Framework Initiative
5